自引率: 4.9%
被引量: 3784
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 4
投稿须知/期刊简介:
Published by Adis International Limited (now part of Wolters Kluwer Health). ISSN: 1170-229X.<br /><br />Drugs & Aging provides you with important and current information on drug use in the aging population as well as diseases of the aging and the effects of aging on drug treatment. By providing peer reviewed, impartial and reliable data, the review articles in Drugs & Aging assist you in making clinical decisions and treatment choices based on international consensus, keeping you well informed on important issues, up to date with emerging treatments, and aware of the place of specific drugs in therapy. The Journal aims to promote optimum drug therapy in older adults by providing a regular programme of review articles covering the most important aspects of clinical pharmacology and patient management in this unique group. Physiological changes during aging which have implications for drug therapy also fall within the scope of the Journal.
期刊描述简介:
Published by Adis International Limited (now part of Wolters Kluwer Health). ISSN: 1170-229X. Drugs & Aging provides you with important and current information on drug use in the aging population as well as diseases of the aging and the effects of aging on drug treatment. By providing peer reviewed, impartial and reliable data, the review articles in Drugs & Aging assist you in making clinical decisions and treatment choices based on international consensus, keeping you well informed on important issues, up to date with emerging treatments, and aware of the place of specific drugs in therapy. The Journal aims to promote optimum drug therapy in older adults by providing a regular programme of review articles covering the most important aspects of clinical pharmacology and patient management in this unique group. Physiological changes during aging which have implications for drug therapy also fall within the scope of the Journal.
-
Fall Outcomes in Older Adults Following Benzodiazepine/Z-Drug Discontinuation: A Retrospective Cohort Study in an Academic Health System.
被引量：- 发表：1970
-
Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects.
被引量：- 发表：1970
-
Trends in Drug Duplications in Swedish Older Adults: A Nationwide Register Study from 2006 to 2021.
被引量：- 发表：1970
-
Prospective Monitoring of New Drugs in Older Adults with and without Frailty: Near-Real-Time Assessment of Effectiveness and Safety of Oral Anticoagulants in Medicare Data.
Prospective sequential analyses after a new drug approval allow proactive surveillance of new drugs. In the current study, we demonstrate feasibility of frailty-specific sequential analyses for dabigatran, rivaroxaban, and apixaban versus warfarin. We partitioned Medicare data from 2011 to 2020 into datasets based on calendar year following the date of drug approval. Each calendar year of data was added sequentially for analysis. We used a new-user, active comparative design by comparing the initiators of dabigatran versus warfarin, rivaroxaban versus warfarin, and apixaban versus warfarin. Patients aged ≥ 65 years with atrial fibrillation without contraindication to the anticoagulants were included. Claims-based frailty index ≥ 0.25 was used to define frailty. The initiators of each direct oral anticoagulant were propensity-score matched to the initiators of warfarin within each frailty status. The effectiveness outcome was ischemic stroke or systemic thromboembolism, and the safety outcome was major bleeding. For each calendar year, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazards models using all data available up to that year. As an example of the results, in the 2020 dataset, compared with warfarin, apixaban was associated with a reduced risk of ischemic stroke or systemic thromboembolism (frail: HR 0.73, 95% CI 0.63-0.85; non-frail: HR 0.65, 95% CI 0.59-0.72) and major bleeding (frail: HR 0.63, 95% CI 0.57-0.69; non-frail: HR 0.59, 95% CI 0.56-0.63) in both frail and non-frail patients. We found evidence for apixaban's effectiveness and safety within 1-2 years after the drug approval in frail older patients. Our frailty-specific sequential analyses can be applied to future near-real-time monitoring of newly approved drugs.
被引量：- 发表：1970
-
Correction: Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.
被引量：- 发表：2024
